Regulatory sanctions for ethically relevant GCP violations
Files
Publication date
2019-11
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by_nc_nd
Abstract
Although EU inspectors and clinical assessors are mandated to identify and act upon ethical issues, regulators lack guidance on how this can be done. Hence, we propose a four-step regulatory approach on ethically relevant GCP violation findings. The first step is identification of the ethical issue. Next is analysis [i.e., identifying the gravity (intensity or severity) and the magnitude (amount and duration) of the ethics violation as well as the responsible person(s) or entity or entities]. The third step is evaluation, (i.e., the process of deliberating to determine the significance of the ethics violation, with the intention of identifying the most reasonable sanction and/or corrective or reparative action). Last is decision-making or the process of choosing and implementing a regulatory course of action.
Keywords
Pharmacology, Drug Discovery
Citation
Bernabe, R D L C, van Thiel, G J M W, Breekveldt, N S, Gispen, C C & van Delden, J J M 2019, 'Regulatory sanctions for ethically relevant GCP violations', Drug Discovery Today, vol. 24, no. 11, pp. 2116-2119. https://doi.org/10.1016/j.drudis.2019.07.001